ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ZP6590

A development code. Also written as “ZP6590, solution for injection”.

Its studies are mostly in Obesity, led by Zealand Pharma.

Furthest: early phase 1, since Jul 16, 20261 company-led study, 1 open or runningNext primary completion: Sep 6, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma11 open or runningearly phase 1since Jul 16, 2026Jul 16, 2026Sep 6, 2027early phase 1 · NCT07721597

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2026First study: early phase 1 study in OverweightFirst studyNCT07721597 · 88 planned · Germany

Ahead

  1. Sep 6, 2027Primary completion: early phase 1 study in OverweightNCT07721597

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07721597Overweight · GermanyEarly 1RecruitingSep 6, 202788

How it is read

Names in the registry

  • “ZP6590, solution for injection”, 1 entry

Codes read as this program: ZP6590.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.